Coronavirus Update

FDA Authorizes First Covid-19 and Flu Combination Test for Use with Home-Collected Samples

The U.S. Food and Drug Administration authorized the first diagnostic test for at home collection of patient samples to detect both Covid-19 and influenza A and B (flu).

The FDA authorized Quest Diagnostics RC Covid-19 +Flu RT-PCR Test for prescription use with the Quest Diagnostics Self-Collection Kit for Covid-19 +Flu by individuals who are suspected of respiratory viral infection consistent with Covid-19 when home collection is determined to be appropriate by an individual’s healthcare provider. Under a health care provider’s order, patients can collect a sample at home and ship it to a Quest Diagnostics laboratory for analysis following the instructions included with the self-collection kit.

More details on the FDA website.

06.12.2020

News • "COMPASS" method

Using nanoparticles for more sensitive rapid tests

A newly developed rapid test needs only a few seconds to reliably detect pathogens such as SARS-CoV-2. It is based on specially designed magnetic nanoparticles.

News • Machine learning approach for screening

AI model predicts results of Covid-19 tests

A new study demonstrates that AI models, using symptom and demographic features, can help predict Covid-19 infections, providing a way for rapid screening and cost-effective infection detection.

News • Appeal for sustainability

POCT: Why the medical sector must tackle its single-use diagnostic waste

During the Covid-19 pandemic, the use of these single-use diagnostics, or point-of-care tests has exploded. This is having major environmental consequences, experts point out.